In June 2021, the world was informed about a new drug for Alzheimer's disease approved
by the FDA. Aducanumab (BIIB037, ADU), being a monoclonal antibody IgG1, is the newest …

The emergence of large-scale human genome projects, advances in DNA sequencing
technologies, and the massive volume of electronic medical records [EMR] shift the …

Traditional Chinese medicine (TCM) has guided health maintenance and disease treatment
for thousands of years and has been widely used in many countries around the world. TCM …

Alzheimer's Disease (AD) is a neurodegenerative disease that affects cognition and is the
most common cause of dementia in the elderly. As the number of elderly individuals …

The expeditious advancement of Alzheimer's Disease (AD) is a threat to the global
healthcare system, that is further supplemented by therapeutic failure. The prevalence of this …

This decade has seen the beginning of ground-breaking conceptual shifts in the research of
Alzheimer's disease (AD), which acknowledges risk elements and the evolving wide …

Extracellular vesicles (EVs), secreted membranous nano-sized particles, are critical
intercellular messengers participating in nervous system homeostasis, while recent …

Alzheimer's disease (AD) includes a long asymptomatic stage, which precedes the formal
diagnosis of dementia. AD biomarker models provide a framework for precision medicine …

Accumulating evidence mainly from observational studies supports the notion that lifestyle
factors such as regular physical activity can modulate potential risk factors of dementia …

Background: Research on predictors of working memory training responsiveness, which
could help tailor cognitive interventions individually, is a timely topic in healthy aging …